(“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the ...
IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with ...
Pre-conference AI in pharmacometrics workshop and four scientific poster presentations highlight PumasAI’s presence at the ...
Numerical instability, the gain or loss of whole chromosomes, has received far less attention despite its frequency in ...
Merck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could ...
October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly ...
Bristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival ...
Patients had adverse events after receiving a Fresenius Kabi medicine that experienced manufacturing deviations.
Despite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as ...
The Speak Foundation is pleased to announce a $300,000 commitment over two years from BridgeBio Pharma, Inc. to support and ...
Amid rising industry concerns about U.S. competitiveness with China, the Trump administration is rolling out four ARPA-H ...
Childress brings nearly 20 years of experience leading U.S. and global healthcare marketing, product management and brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results